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C1q nephropathy: A variant of focal segmental glomeruloscle-
rosis.
Background. C1q nephropathy is a poorly understood and
controversial entity with distinctive immunopathologic fea-
tures. In order to better define the clinical-pathologic spectrum,
we report the largest single-center series.
Methods. Nineteen biopsies with C1q nephropathy were
identified from among 8909 native kidney biopsies received
from 1994 to 2002 (0.21%). Defining criteria included (1) domi-
nant or co-dominant immunofluorescence staining for C1q,
(2) mesangial electron dense deposits, and (3) no clinical or
serologic evidence of systemic lupus erythematosus (SLE).
Results. The 19 patients were predominantly African Ameri-
can (73.7%), female (73.7%), young adults and children (range,
3 to 42 years; mean, 24.2 years). Presentation included ne-
phrotic range proteinuria (78.9%), nephrotic syndrome (50%),
renal insufficiency (27.8%), and hematuria (22.2%). No patient
had hypocomplementemia or evidence of underlying autoim-
mune or infectious disease. Renal biopsy revealed focal seg-
mental glomerulosclerosis (FSGS) in 17 (including six collaps-
ing and two cellular) and minimal-change disease (MCD) in
two. All biopsies displayed co-deposits of immunoglobulin G
(IgG), with more variable IgM (84.2%), IgA (31.6%), and C3
(52.6%). Foot process effacement varied from 20% to 100%
(mean, 51%). Twelve of 16 patients with available follow-up
received immunosuppressive therapy. One patient had com-
plete remission of proteinuria and six had partial remission.
Four patients with FSGS pattern had progressive renal insuffi-
ciency, including two who reached end-stage renal disease
(ESRD). Median time from biopsy to ESRD was 81 months.
On multivariate analysis, the best correlate of renal insuffi-
ciency at biopsy and at follow-up was the degree of tubular
atrophy and interstitial fibrosis (P 0.0495 and 0.0341, respec-
tively).
Conclusion. C1q nephropathy falls within the clinical-patho-
logic spectrum of MCD/FSGS. Although further studies are
needed to determine the pathomechanism of C1q deposition,
we hypothesize that it may be a non-specific marker of in-
creased mesangial trafficking in the setting of glomerular pro-
teinuria.
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C1q nephropathy is a controversial entity that was first
defined by its unusual immunopathologic characteristics.
As originally described by Jennette and Hipp in 1985 [1],
C1q nephropathy manifests dominant or co-dominant
immunofluorescence staining for C1q in a predominantly
mesangial distribution. Although the glomerular changes
bear some resemblance to lupus nephritis, all 15 patients
initially reported had negative antinuclear antibody se-
rologies, normal serum complements, and no clinical evi-
dence of systemic lupus erythematosus (SLE). The 15
patients presented in their second or third decade (age
range, 14 to 27 years; mean, 17.8 years), without racial or
gender predominance. Presentation was with proteinuria
(mean, 7.5 g/day) and serum creatinine less than or equal
to 1.5 mg/dL. Forty percent of patients also had evidence
of hematuria. None of the nine patients treated with
steroids had resolution of proteinuria, suggesting a poor
outcome.
In their initial description of C1q nephropathy, Jen-
nette and Hipp [1] described a wide spectrum of patho-
logic findings. Light microscopic evaluation was available
in 13 cases and revealed no significant glomerular abnor-
mality (two cases), mesangial proliferation (three cases),
focal proliferative glomerulonephritis (five cases), and
diffuse proliferative glomerulonephritis (three cases) [1].
All cases stained positively by immunofluorescence for
C1q with a mean intensity of 3.6 (range, 0.5 to 4). The
staining for C1q was dominant in 12 cases, co-dominant
with IgG in two cases, and 3 in a single case with 4
staining for C3 [1]. In addition to C1q, staining for IgG,
IgM, and C3 was identified in all cases. Electron micros-
copy revealed mesangial deposits in all cases, as well as
subendothelial and subepithelial deposits in three and
two cases, respectively. Endothelial tubuloreticular in-
clusions were not identified. C1q nephropathy was pres-
ent in 15 of 800 biopsies examined, for a biopsy incidence
of 1.9% [1].
A subsequent report by Iskandar, Browning, and Lo-
rentz [2] described 15 pediatric patients with C1q ne-
phropathy (age range, 2 to 16 years), including 10 female
and 11 Caucasian subjects [2]. Nine children met criteria
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for nephrotic syndrome and had been treated unsuccess-
fully with steroids prior to renal biopsy. Five were non-
responsive, two became steroid-dependent, and two were
frequent relapsers. Among the remaining six patients,
four had a nephritic presentation and two had persist-
ent proteinuria. Light microscopy revealed no histologic
abnormalities in eight cases [analogous to minimal-
change disease (MCD)], focal segmental glomeruloscle-
rosis (FSGS) in four cases, and FSGS with mesangial
proliferation in three cases. Immunofluorescence re-
vealed dominant or co-dominant staining for C1q in 13 of
15 cases. Ultrastructural evaluation disclosed mesangial
deposits and the absence of endothelial tubuloreticular
inclusions. Outcomes were poor in patients presenting
with nephrotic syndrome, in particular those with histo-
logic findings of FSGS [2]. However, patients presenting
with nephritic syndrome or subnephrotic proteinuria
maintained normal renal function despite the absence
of treatment [2].
To enlarge our understanding of this rare condition,
we report the largest single-center series of C1q nephrop-
athy. Our findings suggest that this entity falls within
the clinicopathologic spectrum of idiopathic FSGS/MCD
and that prognosis is more favorable than previously
recognized.
METHODS
All native renal biopsies received and processed at
Columbia Presbyterian Medical Center from 1994 to
2002 (N  8909) were reviewed retrospectively for the
diagnosis of C1q nephropathy. C1q nephropathy was
defined by (1) the presence of mesangial immune depos-
its that stain dominantly or co-dominantly for C1q; (2)
corresponding mesangial electron dense deposits by elec-
tron microscopy; and (3) negative antinuclear antibody
(ANA) and absence of clinical evidence of SLE. Nine-
teen cases of C1q nephropathy were received from 17
nephrologists at 12 hospitals in four states, for a biopsy
incidence of 0.21%. All cases were processed for light
microscopy, immunofluorescence, and electron micros-
copy according to standard techniques and, in all cases,
glomerular tissue was available for all three modalities
of evaluation. Among biopsies that displayed FSGS, a
recently constructed classification system [3] was utilized
to subtype the histologic variants of FSGS. Briefly, the
cellular variant of FSGS was defined by the presence of
at least one glomerulus with segmental endocapillary
hypercellularity causing occlusion of the capillary lumen/
lumina. The endocapillary cells typically include foam
cells, macrophages, and endothelial cells. The collapsing
variant of FSGS was defined by wrinkling and retraction
of the glomerular basement membrane (“collapse”) with
hypertrophy and hyperplasia of the overlying podocytes.
Tubular atrophy and interstitial fibrosis and interstitial
inflammation were graded on a scale of mild, moderate,
and severe corresponding to 0% to 25%, 26% to 50%,
and 51% to 100% of the cortex sampled, respectively.
Similarly, the degree of vascular disease was graded as
mild, moderate, and severe based on the extent of lumi-
nal narrowing. For immunofluorescence, 3 m cryostat
sections were stained with fluorescein isothiocyanate
(FITC)-conjugated rabbit antihuman IgG, IgM, IgA, C3,
C1q, kappa light chain and lambda light chain (Dako
Corporation, Carpinteria, CA, USA). The intensity of
immunofluorescence positivity was graded on a scale of
0, trace; and 1 to 3. Electron microscopy was performed
with a JEOL 100S electron microscope (Akishima, Japan).
Patient charts were reviewed retrospectively for pre-
senting symptoms and laboratory findings, clinical evi-
dence of SLE, treatment, and follow-up. For the purpose
of establishing clinical definitions, patients 18 years of
age were considered adults and patients 18 years of
age were considered children. For adults, the following
definitions were utilized: nephrotic range proteinuria, 24-
hour urine protein 3 g/day; hypoalbuminemia, serum
albumin3.5 g/dL; hypercholesterolemia, serum choles-
terol 200 mg/dL; renal insufficiency, serum creatinine
1.2 mg/dL; and hematuria, 5 red blood cells per high
power field on microscopic examination of the urinary
sediment. Nephrotic syndrome was defined as nephrotic
range proteinuria, hypoalbuminemia, and peripheral
edema. Hypertension was defined as systolic blood pres-
sure140 mm Hg or diastolic blood pressure90 mm Hg.
For children, nephrotic range proteinuria was defined
as 40 mg/m2/hour [4]; hypoalbuminemia was defined
as serum albumin 2.5 g/dL [4]; and renal insufficiency
was defined by a calculated creatinine clearance less than
90 mL/min, normalized for body surface area [5]. Hyper-
tension was defined as a systolic or diastolic blood pres-
sure greater than the 90th percentile based on the child’s
gender, age, and height percentile [6].
For the purpose of outcomes analysis, the following
definitions were utilized. Stable renal function was de-
fined as a change in serum creatinine of 20% of the
initial value. Complete remission was defined as a 24-
hour urine protein of300 mg/day and stable renal func-
tion at last follow-up. Partial remission was defined by
the presence of a 24-hour urine protein of 2 g/day, a
reduction in proteinuria of at least 50%, and stable renal
function at last follow-up.
Statistical analyses
Statistical analysis was performed using exact statisti-
cal methods for nonparametric data utilizing SPSS for
Windows, version 11.5 (SPSS, Inc., Chicago, IL, USA)
and StatXact (version 5.0) and LogXact (version 5.0) for
Windows (Cytel Corp., Cambridge, MA, USA). Statisti-
cal tests used, as appropriate, included the Fisher exact
test, Kruskal-Wallis test, and the Jonckheere-Terpstra
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Table 1. Patient demographics
Total number of patients 19








African American 14 73.7%
Hispanic 3 15.8%
test. Life-table analysis was performed using the method
of Kaplan and Meier and analyzed by the log rank test.
Multivariate analysis was performed by logistic regres-
sion analysis and by the Cox proportional hazards model.
Statistical significance was assumed at P 0.05. Continu-
ous variables are reported as mean  the standard error
of the mean (SEM).
RESULTS
This cohort of 19 patients with C1q nephropathy in-
cluded 14 females and 5 males (Table 1). Patient ages
ranged from 3 to 42 years (mean, 24.2 years) and were
notable for a clustering of seven cases between the ages
of 11 and 15 years. Fourteen patients were African
American, two were Caucasian, and three were Hispanic.
Laboratory and clinical findings at the time of renal
biopsy are summarized in Table 2. The mean serum
creatinine was 1.17 mg/dL and five patients (27.8%) had
evidence of renal insufficiency. The mean 24-hour urine
protein was 8.1 g/day and the mean serum albumin was
2.8 g/dL. While 15 patients (78.9%) had nephrotic range
proteinuria, only nine (50%) had hypoalbuminemia; all
nine patients with hypoalbuminemia had evidence of
edema and therefore met criteria for full nephrotic syn-
drome (50%). The incidence of edema, hypercholester-
olemia, and hematuria was 58.8%, 88.9%, and 22.2%,
respectively. Of note, none of the four patients with
hematuria had evidence of red blood cell casts on micro-
scopic examination of the urinary sediment. At the time
of biopsy, five of 17 patients (29.4%) were hypertensive.
Due to the previous report suggesting that C1q ne-
phropathy may resemble lupus nephritis [1], SLE was
carefully excluded in all patients. ANA studies were
universally negative and, in all cases with available data,
serum complements were within normal limits. Ten pa-
tients were tested for human immunodeficiency virus
(HIV) infection and all were negative. Three patients
were obese but no patient had evidence of diabetes melli-
tus. Two patients were initially found to have proteinuria
Table 2. Renal presentation
Mean serum creatinine mg/dL 1.170.15 Range, 0.3–3.2
Renal insufficiencya 5/18 27.8%
Mean 24 hour urine protein g/day 8.11.4 Range, 1.5–23
Nephrotic range proteinuriaa 15/19 78.9%
Mean serum albumin g/dL 2.80.24 Range, 1.0–4.4
Hypoalbuminemiaa 9/18 50%
Peripheral edema 10/17 58.8%
Full nephrotic syndromea 9/18 50%




Positive antinuclear antibodies 0/19
Depressed serum complements 0/17
Positive HIV serologies 0/10
HIV is human immunodeficiency virus.
aClinical terms are defined in Methods section of text
during pregnancy, one of which was associated with pre-
eclampsia.
The renal biopsy findings are outlined in Table 3. The
most common pattern of glomerular disease was FSGS,
present in 17 of 19 biopsies (89.5%) (Fig. 1A). Subtyping
of the pattern of FSGS revealed nine patients with dis-
crete segmental scars typical of the classic form of FSGS
or FSGS “not otherwise specified” (Fig. 1B), six patients
with the collapsing variant (Fig. 1C), and two with the
cellular variant (Fig. 1D) [3]. Of note, biopsies from
all 14 African American patients revealed FSGS. The
remaining two biopsies exhibited extensive foot process
effacement on ultrastructural analysis, consistent with
MCD. In these two biopsies, the number of glomeruli
sampled for light microscopy was 18 and 6; thus, the
possibility of unsampled FSGS could not be completely
excluded. By light microscopy, one case of MCD had
normal-appearing glomeruli and the other exhibited a
diffuse increase in mesangial cells, consistent with “dif-
fuse mesangial hypercellularity.” Mesangial hypercellu-
larity, defined as greater than three mesangial cells per
mesangial cell area, was identified in 10 of the 17 biopsies
exhibiting FSGS (58.8%) (Fig. 1E). In some cases, para-
mesangial deposits were visible at the light microscopic
level with the trichrome stain (Fig. 1F). The degree of
tubular atrophy and interstitial fibrosis, interstitial in-
flammation, and vascular disease was absent or mild in
73.7%, 63.2%, and 94.7% of biopsies, respectively.
Immunofluorescence revealed dominant or co-domi-
nant staining for C1q in all cases (Fig. 1G). The pattern of
staining was mesangial in all cases, often with a comma-
shaped appearance; two cases also displayed semilinear
segmental capillary wall positivity. There was positive
staining for IgG, C1q, kappa, and lambda in all cases,
whereas staining for IgM (84.2% of cases), IgA (31.6%),
and C3 (52.6%) was less consistent. “Full house” staining
for IgG, IgM, IgA, C3, and C1 was identified in 4 of 19
cases (21.1%). The mean intensity of staining for C1q
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Table 3. Pathologic findings
Light microscopy
Pattern of glomerular disease
Focal segmental glomerulosclerosis 17 89.5%
Collapsing variant 6/17 35.5%
Cellular variant 2/17 11.8%
Not otherwise specified 9/17 52.9%
Minimal change disease 2 10.5%
Mean number of glomeruli sampled 21.02.5 Range, 6–42
Mean number globally sclerotic
glomeruli 3.11.2
Mean number segmentally sclerotic
glomeruli 5.20.8
Mesangial proliferation 11/19 57.9%







Pattern of glomerular staining
Mesangial 17 89.5%




Positive staining for IgG 19/19 100%; MI 1.39
Positive staining for IgM 16/19 84.2%; MI 1.06
Positive staining for IgA 6/19 31.6%; MI 0.83
Positive staining for C3 10/19 52.6%; MI 1.20
Positive staining for C1q 19/19 100%; MI 2.05
Positive staining for kappa light chain 18/18 100%; MI 1.00
Positive staining for lambda light chain 18/18 100%; MI 1.14
Electron microscopy
Distribution of electron dense deposits
Global mesangial 10 52.6%
Segmental mesangial 7 36.8%
Global mesangial and segmental
capillary wall 2 10.5%
Mean percentage of foot process
effacement 51.17.4
Endothelial tubuloreticular inclusions 1/19 5.3%
MI is mean intensity of immunofluorescence positivity.
was 2.05 (scale, 0 to 3), which far exceeded the mean
intensity of the next most intense stain, IgG (mean inten-
sity, 1.39) (Fig. 2).
Electron microscopy confirmed the presence of elec-
tron dense deposits in all biopsy samples (Fig. 1H). The
deposits had a mesangial distribution in all cases and
ranged from segmental (seven cases) to global (12 cases).
In general, the mesangial deposits predominated in “para-
mesangial” regions, subjacent to the reflection of the
glomerular basement membrane over the mesangium.
In two cases with global mesangial deposits, segmental
subendothelial deposits were also identified. The mean
percentage of foot process fusion was 51.1% (range, 20%
to 100%). A rare endothelial tubuloreticular inclusion
was identified in only one of 19 cases.
Clinical follow-up was available in 16 of 19 patients
(84.2%) and the mean follow-up period was 27.1 months
(Table 4). Twelve patients received immunosuppressive
therapy, including steroids alone in seven patients, ste-
roids plus cyclosporine in four patients, and steroids,
cyclosporine, and cytoxan in one patient. In two pediatric
patients with collapsing FSGS pattern, biopsies were per-
formed after failure to respond to an 8-week course of
corticosteroids, and both were subsequently treated with
cyclosporine. Multiple patients received an angiotensin-
converting enzyme (ACE) inhibitor or angiotensin recep-
tor blocker; unfortunately, data concerning angiotensin
blockade were incomplete and therefore details cannot
be provided. Within the period of time with available
follow-up, 12 patients (75%) had stable renal function.
Among the remaining four patients, two had a mild in-
crease in serum creatinine (from 1.0 to 1.3 mg/dL over
79 months and from 0.8 to 1.1 mg/dL over 3 months)
and two with initial creatinines of 1.7 and 3.2 mg/dL
progressed to end-stage renal disease (ESRD).
Follow-up 24-hour urine protein quantitation was
available in 11 patients: one had a complete remission,
six had a partial remission, and four had unremitting
proteinuria. Two additional patients progressed to ESRD
and were therefore characterized as having unremitting
disease despite the absence of repeat quantitation of
proteinuria. Of note, at the completion of follow-up,
there was a mean decline in proteinuria of 5.7 g/day (P
0.011) and only one of 11 patients had developed greater
proteinuria than at the start of the study.
There was no significant relationship between out-
come and either the method of treatment or the light
microscopic pattern of glomerular disease (Table 5). The
six patients with a partial remission were treated with
steroids (two patients), steroids plus cyclosporine (three
patients), or no immunosuppressive therapy (one pa-
tient). Biopsies from the patients with a partial remission
included three cases of FSGS “not otherwise specified,”
one cellular FSGS, one collapsing FSGS, and one MCD.
The single patient undergoing complete remission had
MCD that was treated with steroids.
On univariate analysis, patients with renal insuffi-
ciency at presentation had a higher percentage of glomer-
uli with segmental sclerosis (P 0.043), a greater degree
of tubular atrophy and interstitial fibrosis (P  0.025),
and more extensive foot process fusion (P  0.05). The
degree of proteinuria correlated best with the subtype
of FSGS, with the greatest degree of proteinuria seen in
patients with collapsing FSGS (P 0.005). Full nephrotic
syndrome was seen in two of nine patients with FSGS
not otherwise specified (22.2%) and one of two patients
with cellular FSGS (50%) versus all five patients with
collapsing FSGS (100%; P  0.026). Among the two
patients with MCD, one had full nephrotic syndrome
and the other was a 3-year-old Caucasian female with a
urine protein-to-creatinine ratio of 2.2, a serum albumin
of 3.3 gm/dL, and no evidence of edema. At the conclu-
sion of the follow-up peroid, the best predictor of stable
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Fig. 2. Immunofluorescence findings in C1q nephropathy. This double-
bar graph depicts the prevalence (left axis) and mean intensity (right
axis) of immunofluorescence staining in all 19 cases of C1q nephropathy.
The corresponding numerical values are provided in Table 3.
Table 4. Clinical follow-up
Follow-up available 16/19 84.2%
Mean follow-up time months 27.17.4 Range, 3–81
Immunosuppressive therapy
Steroids 7 43.8%
Steroids plus cyclosporine 5 31.3%
None 4 25.0%
Outcome of renal functiona,b
(N  16)
Stable 12 75%




(300 mg/day  SRF) 1/13 7.7%
Partial remission (2 g/day 
50% reduction in
proteinuria  SRF) 6/13 46.2%
No remission 6/13 46.2%
SRF is stable renal function.
aStable renal function defined as 20% increase in serum creatinine
bThe two patients with C1q/minimal change disease comprised one partial and
one complete remission; both had stable renal function at the end of follow-up
renal function was the inverse of the degree of tubular
atrophy and interstitial fibrosis (P  0.017). No single
parameter was found to be predictive of remission of
disease. On multivariate analysis using logistic regres-

Fig. 1. Pathologic findings in C1q nephropathy. (A ) Low power view shows focal and segmental glomerulosclerosis affecting two of three glomeruli.
The uninvolved glomerulus appears unremarkable. There is patchy tubular atrophy and interstitial fibrosis associated with mild chronic interstitial
inflammation [Periodic acid-Schiff (PAS),	100]. (B ) A representative glomerulus displays focal segmental glomerulosclerosis (FSGS) not otherwise
specified with a discrete lesion of segmental sclerosis affecting half of the tuft. There is capping of the overlying podocytes (PAS, 	400). (C ) A
glomerulus shows a collapsing lesion of sclerosis with segmental obliteration of the capillary lumina by wrinkling of the glomerular basement
membrane. There is marked hypertrophy and hyperplasia of the podocytes, many of which contain PAS positive protein resorption droplets (PAS,
	250). (D ) This glomerulus displays a cellular lesion of segmental sclerosis with expansion of the capillary lumen by endocapillary foam cells.
The adjacent segments of the glomerulus have mild mesangial hypercellularity [hematoxylin and eosin (H&E), 	400]. (E ) An example of C1q
nephropathy with mild global mesangial hypercellularity. Other glomeruli (not illustrated) from this biopsy displayed FSGS (H&E, 	400). (F )
On high power examination, fuchsinophilic deposits that expand the mesangium can be identified with the trichrome stain (see arrows) (	630).
(G ) Immunofluorescence staining for C1q shows global, high-intensity positivity outlining the mesangial areas, with a comma-like appearance
(	400). (H ) Electron micrograph shows a mesangial electron-dense deposit beneath the glomerular basement membrane reflection over the
mesangium (an area often referred to as “paramesangial”). No electron dense deposits are seen involving the peripheral glomerular capillary
walls. There is mild foot process effacement (	2000).
Table 5. Clinical outcomes according to pathologic findings
and treatment (N  13)
Clinical outcome Pattern of disease Immunosuppressive therapy
Complete
remission MCD Steroids
Partial remission MCD Steroids, cyclosporine, cytoxan
FSGS NOS Steroids
FSGS NOS None
FSGS NOS Steroids, cyclosporine
FSGS cellular Steroids
FSGS collapsing Steroids, cyclosporine




FSGS collapsing Steroids, cyclosporine
FSGS collapsing None
Abbreviations are: MCD, minimal change disease; FSGS, focal segmental
glomerulosclerosis; NOS, not otherwise specified.
sion, the best correlate of renal insufficiency at time of
biopsy and at the conclusion of follow-up was the degree
of tubular atrophy and interstitial fibrosis (P  0.0495
and P  0.0341, respectively). Life-table analysis by the
method of Kaplan-Meier disclosed a median time from
biopsy to ESRD of 81.0 months in both the total study
population and in the subgroup of patients with light
microscopic findings of FSGS.
DISCUSSION
The validity of C1q nephropathy as a distinct clinical-
pathologic entity has been questioned. Review of the
literature reveals that the term has been applied to a
wide spectrum of pathologic lesions from MCD to FSGS
to various proliferative patterns of glomerulonephritis
[1, 2, 7–13]. Our understanding of this entity has been
hindered by the paucity of large series.
The term “C1q nephropathy” was first applied by Jen-
nette and Hipp [1] in 1985 to biopsies exhibiting (1)
dominant or co-dominant staining for C1q, (2) confir-
mation of mesangial deposits by electron microscopy,
and (3) the absence of clinical or serologic evidence of
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SLE. In this initial study, the spectrum of light micro-
scopic findings ranged from “normal” to mesangial pro-
liferative to diffuse proliferative glomerulonephritis,
similar to the range of findings seen in lupus nephritis.
Applying the same three inclusion and exclusion criteria,
Iskandar, Browning, and Lorentz [2] subsequently re-
ported a series of 15 children with C1q nephropathy. In
their experience, C1q nephropathy appeared to fit best
within the morphologic spectrum of MCD and FSGS.
Similar to the previous study [1], the most common pre-
sentation was proteinuria, with or without full nephrotic
syndrome.
Utilizing the three criteria put forth by Jennette and
Hipp [1], we report the largest series to date on C1q
nephropathy. In our experience, C1q nephropathy is an
entity that histologically falls within the MCD/FSGS con-
tinuum and appears to exhibit the full spectrum of his-
tologic variants seen in FSGS. Our cohort consisted of
19 patients who were predominantly African American
(73.7%), female (73.7%), and between 10 and 30 years
of age (63.2%). All patients presented with proteinuria,
which was nephrotic range in 78.9% and was associated
with full nephrotic syndrome in 50%. A minority of pa-
tients had renal insufficiency (27.8%), hematuria (22.2%),
or hypertension (29.4%). Light microscopic evaluation
disclosed MCD (two cases), FSGS not otherwise speci-
fied (nine cases), collapsing FSGS (six cases), and cellular
FSGS (two cases). Similar to the two previous large
series on C1q nephropathy [1, 2], mesangial hypercellu-
larity was commonly seen (57.9%). However, in contrast
to the findings of Jennette and Hipp [1], none of our
cases had endocapillary proliferation or leukocyte infil-
tration typical of a proliferative glomerulonephritis, al-
though two showed segmental endocapillary hypercel-
lularity most consistent with the cellular variant [3] of
FSGS. In all cases, the disease appeared idiopathic, with-
out evidence of systemic infections or autoimmune dis-
ease. Moreover, no patient had hypocomplementemia
typical of systemic complement activation by circulating
immune complexes. Outcomes were generally good, with
seven of 13 patients (53.8%) entering partial or complete
remission (with or without immunosuppressive therapy)
over a mean follow-up period of 27.1 months. Further-
more, 12 of 16 patients (75%) had stable renal function
at the conclusion of follow-up.
There have been multiple smaller reports on C1q ne-
phropathy. Davenport, Maciver, and Mackenzie [7]
reported four adult patients with C1q nephropathy. Pat-
terns of glomerular disease included membranoprolifer-
ative glomerulonephritis type III, diffuse proliferative
glomerulonephritis, FSGS, and membranous glomerulo-
nephritis. All four patients met inclusion criteria for the
diagnosis of C1q nephropathy and had nephrotic syn-
drome and renal insufficiency. However, two of three
had hypocomplementemia. At follow-up, three patients
underwent spontaneous remission. The fourth patient,
in whom renal biopsy revealed FSGS, had a complete
remission following treatment with steroids and cyclo-
sporine. Shappell, Myrthil and Fogo [8] reported a 16-
year-old African American male with relapsing, steroid-
resistant nephrotic syndrome due to C1q nephropathy
with light microscopic findings of FSGS. Ekim et al [9]
described a 9-year-old boy with nephrotic syndrome,
atopic dermatitis, and C1q nephropathy with MCD who
had a rapid resolution of disease following treatment
with steroids and a subsequent relapse that was steroid-
responsive. While this case appears typical of C1q ne-
phropathy, no deposits were demonstrated by electron
microscopy.
There are also multiple reports of purported “C1q
nephropathy” that differ considerably from previously
reported cases and may not represent bona fide examples
of this disease entity. Kuwano et al [10] reported a case
of congenital nephrotic syndrome with C1q deposits that
spontaneously improved over 12 months in the absence
of immunosuppressive therapy. The congenital presenta-
tion and spontaneous remission suggest the possibility
of transplacental passage of antibodies as the critical
etiologic factor. Srivastava et al [11] reported the case
of 3-year-old girl with oliguric acute renal failure and
severe crescentic glomerulonephritis with deposits that
stained co-dominantly for C1q and C3. The nephritic
presentation (without nephrotic syndrome), the cres-
centic pattern of glomerulonephritis, the elevated anti-
streptolysin O titer, and the co-dominant staining for
C1q and C3 appear more consistent with an atypical form
of acute postinfectious glomerulonephritis with C1q co-
dominant deposits. Imai et al [12] described a 35-year-
old male with hematuria, proteinuria, weakly positive
ANA, hypocomplementemia and biopsy findings of mes-
angial proliferative glomerulonephritis with C1q-domi-
nant deposits, tubulointerstitial nephritis, and arteri-
olitis. The positive ANA, hypocomplementemia, and
extraglomerular disease suggest the biopsy may repre-
sent an initial manifestation of lupus nephritis. Isaac and
Shihab [13] described a case of de novo C1q nephropathy
in the allograft that was associated with mild mesangial
hypercellularity, “significant” foot process fusion, and
the absence of proteinuria or hematuria. The significance
of C1q staining in the absence of clinical manifestations
is questionable.
Immunofluorescence staining for C1q may be seen in
many glomerular diseases, primarily immune complex-
mediated diseases. Jennette and Hipp [14] compared
staining for C1q in 800 renal biopsies and found high-
intensity positivity in 93% of cases of proliferative lupus
nephritis, 64% of cases of membranous lupus nephritis,
and 56% of cases of membranoproliferative glomerulo-
nephritis (MPGN) type 1 [14]. These findings formed
the basis for their exclusion of SLE in diagnosing C1q
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nephropathy and suggested that the diagnosis of C1q
nephropathy should not be utilized in biopsies that are
otherwise typical of MPGN type 1.
C1, the first component of the complement cascade,
is a pentamer composed of five molecules: a single C1q,
two C1r, and two C1s. The complement cascade begins
when the CH2 domain of an IgG molecule binds to C1q.
This leads to conformational changes that sequentially
activate C1r and C1s and initiate a cascade of down-
stream events. C1q is a large calcium-dependent glyco-
protein that possesses an immunoglobulin binding site
and contains triple helical collagen-like domains. Because
C1q results from complement activation by IgG, it is not
surprising that all of our patients had co-deposits of IgG,
although of generally weaker intensity. Because none of
our patients had hypocomplementemia or evidence of
systemic disease, we speculate that C1q fixes to immuno-
globulin that may become trapped nonspecifically in the
mesangium in the course of glomerular proteinuria due
to increased mesangial trafficking and/or defective clear-
ing of plasma proteins. The ultrastructural localization
of the corresponding electron dense deposits in the para-
mesangial region supports that possibility. This is a site
where small electron densities are not uncommonly seen
as a nonspecific finding in nephrotic syndrome secondary
to MCD or FSGS, where they usually correspond to
mesangial deposits of IgM and/or C3 and C1q [15]. In
the absence of history of autoimmune disease, it is un-
likely that the deposits of IgG and C1q result from anti-
body to C1q, as may occur in lupus nephritis [16].
Our cohort is the first to provide evidence that C1q
nephropathy does not necessarily portend a poor prog-
nosis. Among 11 patients with C1q nephropathy and
FSGS pattern, five (45.5%) had a partial remission. This
included one untreated patient with FSGS, one with
FSGS treated with steroids, one with FSGS treated with
steroids plus cyclosporine, one with collapsing FSGS
treated with steroids and cyclosporine, and one with
cellular FSGS treated with steroids alone. Overall, seven
of 11 patients (63.6%) with C1q nephropathy/FSGS had
stable renal function and two patients (18.2%) pro-
gressed to ESRD. The median renal survival in C1q
nephropathy/FSGS was 81.0 months. Similarly, among
the seven biopsies with C1q nephropathy/FSGS de-
scribed by Iskandar, Browning, and Lorentz [2], follow-
up was available on four patients and included a decrease
in proteinuria in two patients, unchanged proteinuria in
one patient, and ESRD in one patient. For comparison,
a large meta-analysis on FSGS in children and adults
found remission rates (partial or complete) of 28% and
49%, respectively [17]. Furthermore, the outcomes in our
cohort of C1q nephropathy/FSGS compare favorably to
a population of 50 patients with idiopathic FSGS from
our institution who had a mean initial creatinine of 2.0
mg/dL, a mean 24-hour urine protein of 6.9 g/day, a 36%
remission rate, and a mean renal survival time of 62.5
months [18]. Thus, the outcome in our cohort of C1q
nephropathy/FSGS is similar to or better than that re-
ported in the literature for primary FSGS.
Our cohort also included two patients with C1q ne-
phropathy and pathologic findings of MCD. One patient
was treated with steroids and had a complete remission,
whereas the other had a partial remission following ste-
roids, cytoxan, and cyclosporine. Although our experi-
ence is limited to only two patients, Iskandar, Browning,
and Lorentz [2] had eight similar biopsies with C1q ne-
phropathy/MCD. Follow-up was available in six patients
among whom one had a spontaneous remission, two
remitted following treatment with steroids, one was a
frequent relapser, and two were unresponsive to steroids
(one of which progressed to ESRD). The cases reported
by Iskandar, Browning, and Lorentz were biopsied only
after they failed to respond to a course of steroids, which
may have contributed to selection bias. Until more cases
of C1q nephropathy/MCD are pooled from multiple cen-
ters, it is premature to make generalizations about out-
come.
CONCLUSION
Our data strongly suggest that C1q nephropathy falls
within the clinical-pathologic spectrum of FSGS/MCD.
Similar to primary FSGS, it is an idiopathic condition
most common in young adults and children, and exhibits
an African American racial predominance. Patients pres-
ent with heavy proteinuria, often accompanied by ne-
phrotic syndrome, in the absence of systemic disease or
hypocomplementemia. Although mesangial hypercellu-
larity is common, the histologic manifestations are pre-
dominantly those of FSGS, including collapsing and cel-
lular variants. Based on our findings, we recommend that
the absence of hypocomplementemia and the absence of
a membranoproliferative pattern of glomerular disease
be added to the defining criteria for this entity in order
to avoid diagnostic confusion with lupus nephritis and
other established immune complex-mediated glomerulo-
nephritides. Additional studies are needed to determine
the specificity and pathomechanism of C1q deposition
in this condition and to define optimal therapy.
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